Online citations, reference lists, and bibliographies.
← Back to Search

Optimization Of The Preparation Process For Human Serum Albumin (HSA) Nanoparticles.

K. Langer, S. Balthasar, V. Vogel, N. Dinauer, H. von Briesen, D. Schubert
Published 2003 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Nanoparticles prepared by desolvation and subsequent crosslinking of human serum albumin (HSA) represent promising carriers for drug delivery. Particle size is a crucial parameter, in particular for the in vivo behaviour of nanoparticles after intravenous injection. The objective of the present study is the development of a desolvation procedure for the preparation of HSA-based nanoparticles under the aspect of a controllable particle size between 100 and 300 nm in combination with a narrow size distribution. A pump-controlled preparation method was established which enabled particle preparation under defined conditions. Several factors of the preparation process, such as the rate of addition of the desolvating agent, the pH value and the ionic composition of the HSA solution, the protein concentration, and the conditions of particle purification were evaluated. The pH value of the HSA solution prior to the desolvation procedure was identified as the major factor determining particle size. Varying this parameter, (mean) particle diameters could be adjusted between 150 and 280 nm, higher pH values leading to smaller nanoparticles. Washing the particles by differential centrifugation led to significantly narrower size distributions. The reproducibility of the particle size and particle size distribution under the proposed preparation conditions was demonstrated by sedimentation velocity analysis in the analytical ultracentrifuge and the cellular uptake of those nanoparticles was studied by confocal microscope imaging and FACS analysis. The stability of the resulting nanoparticles was evaluated by pH and buffer titration experiments. Only pH values distinctly outside the isoelectric pH range of HSA and low salt concentrations were able to prevent nanoparticle agglomeration.
This paper references
10.1016/S0006-3495(00)76713-0
Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling.
P. Schuck (2000)
10.1023/A:1016064930502
Albumin Nanospheres as Carriers for Passive Drug Targeting: An Optimized Manufacturing Technique
B. Müller (2004)
10.1016/0378-5173(84)90046-2
Analysis of albumin microsphere preparation
J. Gallo (1984)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
10.1016/S0006-291X(05)80083-X
Rapid confirmation and revision of the primary structure of bovine serum albumin by ESIMS and Frit-FAB LC/MS.
K. Hirayama (1990)
10.1016/S0014-5793(99)00364-6
On the mechanism of hepatic transendothelial passage of large liposomes
E. L. Romero (1999)
10.1016/S0939-6411(00)00068-0
Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid.
K. Langer (2000)
10.1016/S0378-5173(00)00590-1
Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups.
C. Weber (2000)
Nanoparticles--a new colloidal drug delivery system.
J. Marty (1978)
10.1023/A:1018965121222
Enhanced Hepatic Uptake of Liposomes Through Complement Activation Depending on the Size of Liposomes
H. Harashima (2004)
10.3109/10611869308996081
Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method.
W. Lin (1993)
10.1016/S0065-3233(08)60640-3
Structure of serum albumin.
D. Carter (1994)
10.1007/3-540-44672-9_5
Characterization of serum albumin nanoparticles by sedimentation velocity analysis and electron microscopy
V. Vogel (2002)
10.1016/0003-2697(85)90442-7
Measurement of protein using bicinchoninic acid.
P. Smith (1985)
10.1016/S0006-3495(02)75469-6
Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems.
P. Schuck (2002)
10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P
Determination of the sedimentation coefficient distribution by least-squares boundary modeling.
P. Schuck (2000)
10.1016/S0378-5173(99)00370-1
Desolvation process and surface characterisation of protein nanoparticles.
C. Weber (2000)



This paper is referenced by
10.1002/smll.200902403
Albumin nanoshell encapsulation of near-infrared-excitable rare-Earth nanoparticles enhances biocompatibility and enables targeted cell imaging.
D. Naczynski (2010)
10.1016/J.IJPHARM.2006.01.010
pH-sensitive hydrogels based on bovine serum albumin for oral drug delivery.
F. Iemma (2006)
10.1039/C2JM16831F
Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery
Lili Xie (2012)
10.1155/2012/686108
Cationic Albumin Nanoparticles for Enhanced Drug Delivery to Treat Breast Cancer: Preparation and In Vitro Assessment
S. Abbasi (2012)
10.1016/j.colsurfb.2014.09.028
Systematic study on the preparation of BSA nanoparticles.
F. Galisteo-González (2014)
10.1016/j.addr.2018.07.006
Top-down fabrication of shape-controlled, monodisperse nanoparticles for biomedical applications.
Xinxin Fu (2018)
10.2147/NSA.S204621
Magnetically controlled protein nanocontainers as a drug depot for the hemostatic agent
A. Prilepskii (2019)
10.1016/j.colsurfb.2017.08.047
Nanoparticulation of bovine serum albumin and poly-d-lysine through complex coacervation and encapsulation of curcumin.
L. Maldonado (2017)
10.1007/978-3-319-13596-0_5
Protein-based nanoparticles
E. Jiménez-Cruz (2015)
10.1016/bs.apcsb.2014.11.004
Food-grade protein-based nanoparticles and microparticles for bioactive delivery: fabrication, characterization, and utilization.
G. Davidov-Pardo (2015)
INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES Human serum albumin nanoparticles for enhanced drug delivery to treat breast cancer: Preparation and In Vitro assessment
R. Singh (2012)
10.1007/s00289-014-1099-0
Long-term release of chlorhexidine from dental adhesive resin system using human serum albumin nanoparticles
H. Kim (2014)
10.1080/02652040601035143
Preparation of sub-100-nm β-lactoglobulin (BLG) nanoparticles
Sanghoon Ko (2006)
10.1016/J.EJPB.2009.02.002
Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage.
M. Holzer (2009)
10.1016/j.jpba.2015.03.031
RP-HPLC method development for the simultaneous determination of timolol maleate and human serum albumin in albumin nanoparticles.
C. Boiero (2015)
Engineered Bovine Serum Albumin Nanoparticles Incorporated Alpha Amylase Preparation for the Improved Activity
Karthick Raja Namasivayam (2014)
10.1016/j.colsurfb.2016.02.019
Self-organization of gliadin in aqueous media under physiological digestive pHs.
M. G. Herrera (2016)
10.4314/TJPR.V12I2.19
Effect of Zeta Potential on the Properties of Nano-Drug Delivery Systems - A Review (Part 2)
S. Honary (2013)
10.1016/J.FOODHYD.2012.03.015
Whey protein nanoparticles prepared with desolvation with ethanol: Characterization, thermal stability and interfacial behavior
İbrahim Gülseren (2012)
10.2174/157341209789649122
Current analytical methods used in the in vitro evaluation of nano-drug delivery systems
A. A. Nagvekar (2009)
10.1039/c9nj05847h
BSA nanoparticles as controlled release carriers for isophethalaldoxime palladacycle complex; synthesis, characterization, in vitro evaluation, cytotoxicity and release kinetics analysis
K. Karami (2020)
10.1016/j.ejpb.2014.01.005
Specific targeting of tumor cells by lyophilisomes functionalized with antibodies.
E. van Bracht (2014)
10.1016/j.ijpharm.2013.08.079
Nanocarriers for intravenous injection--the long hard road to the market.
M. Wacker (2013)
10.1155/2015/987404
A Redox-Sensitive Micelle-Like Nanoparticle Self-Assembled from Amphiphilic Adriamycin-Human Serum Albumin Conjugates for Tumor Targeted Therapy
L. Chen (2015)
10.1016/J.IJPHARM.2007.08.037
Self-assembled drug delivery systems 2. Cholesteryl derivatives of antiviral nucleoside analogues: synthesis, properties and the vesicle formation.
Yiguang Jin (2008)
10.1016/J.JCIS.2007.09.007
Self-assembly of β-casein and lysozyme
X. Pan (2007)
10.1002/JPS.21158
PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug.
D. Sahana (2008)
10.1002/JBM.B.30994
Comparison of ciprofloxacin hydrochloride-loaded protein, lipid, and chitosan nanoparticles for drug delivery.
D. Jain (2008)
10.2147/JEP.S17178
Preparation of ultrasound microbubbles crosslinked to albumin nanoparticles packaged with tissue-type plasminogen activator gene plasmid and method of in vivo transfection
Ji Jun (2011)
10.1002/9783527634057.CH35
Albumin‐Drug Nanoparticles
N. Desai (2011)
10.1016/j.ijpharm.2012.02.028
Folic acid-functionalized human serum albumin nanocapsules for targeted drug delivery to chronically activated macrophages.
A. Rollett (2012)
10.2147/DDDT.S169734
HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment
Yuzhou Shen (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar